Ellevest Inc’s Foghorn Therapeutics FHTX Stock Holding History

Ellevest Inc’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21	Closed	–	–	1680
2022 Q2	$0	Buy	+21	New	+$271	﹤0.01%	1483
2021 Q4	–	Sell	-4	Closed	–	–	1490
2021 Q3	$0	Buy	+4	New	+$44	﹤0.01%	1460

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ellevest Inc's FHTX Position: Q3 2022 in Review

Ellevest Inc sold out of Foghorn Therapeutics (FHTX) in Q3 2022, closing a stake of 21 shares.

Ellevest Inc first reported a position in FHTX in Q3 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 62 funds tracked by Wall St. Rank hold FHTX as of Q3 2022.

Ellevest Inc reported no remaining Foghorn Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 21 Foghorn Therapeutics shares in Q3 2022.
Ellevest Inc first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 2 quarters.
Ellevest Inc's Foghorn Therapeutics position peaked at $0 in Q2 2022.
62 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.